| Phase 11 trial |
|
Phase 1
|
NCT05458219 |
Oct 2022 → Jun 2027 expected |
cancer of unknown primary site |
Innovent Biologics (Suzhou) Co. Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT07025889 |
Jun 2025 → Jun 2026 overdue |
gastric cancer |
Ruijin Hospital |
Recruiting
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07483554 |
Apr 2026 → Mar 2028 expected |
gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma |
Innovent Biologics (Suzhou) Co. Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07483567 |
Apr 2026 → Jun 2030 expected |
gastric adenocarcinoma, gastroesophageal junction adenocarcinoma |
Innovent Biologics (Suzhou) Co. Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07415525 |
Feb 2026 → Dec 2028 expected |
adenocarcinoma, malignant pancreatic neoplasm |
Zhejiang University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06770439 |
Apr 2025 → Jan 2027 expected |
pancreatic adenocarcinoma |
Zhejiang University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06321913 |
Mar 2024 → Dec 2025 |
gastroesophageal adenocarcinoma |
Harbin Medical University |
Unknown
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07066098 |
Aug 2025 → Jun 2027 expected |
malignant pancreatic neoplasm |
Innovent Biologics (Suzhou) Co. Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06238843 |
Jun 2024 → Dec 2026 expected |
gastroesophageal adenocarcinoma |
Innovent Biologics (Suzhou) Co. Ltd. |
Active not recruiting
|
No outcome recorded
|